Clinical Trials

Drug Development Weight Loss Drugs Gene Therapy Major Depressive Disorder Cancer Treatments Alzheimer's Disease Weight Loss Treatments Phase 3 Trials Cancer Treatment Hypertension Drug Safety Drug Efficacy Regulatory Affairs Multiple Myeloma Obesity Treatment Pain Management Eli Lilly Phase 3 Studies Duchenne Muscular Dystrophy Cardiovascular Health Obesity Treatments Tirzepatide Pulmonary Sarcoidosis Efficacy Studies Mental Health Experimental Drugs Cognitive Decline Treatments Gepotidacin Respiratory Diseases Chronic Obstructive Pulmonary Disease Baloxavir Marboxil Pediatric Care Data Integrity Eli Lilly & Company Antiviral Drugs Orforglipron Alopecia Cardiovascular Risk Reduction Treatment Guidelines Nebulized Tyvaso Semaglutide Biopharmaceuticals Product Development Benefit-Risk Assessment Weight Loss Medications Cardiovascular Risk Epilepsy Treatments Lecanemab Olezarsen EMBER-3 Study VTX3232 EMBER-3 Neurological Disorders Lung Cancer Treatments Weight Loss Eczema Atopic Dermatitis Epilepsy Narcolepsy Treatment Phase III Trials Drug Approval Lung Cancer Alcohol Use Disorder COPD Garetosmab Autoimmune Diseases Cannabis Medications Breast Cancer Ulcerative Colitis FDA Advisory Committee DYNE-251 Giredestrant IgA Nephropathy Type 2 Diabetes Risk-Based Oversight Systems NG101 PCSK9 Inhibitors Randomized Controlled Trials Prostate Cancer Drug Heart Failure Rare Diseases Hypertension Treatment GLP-1 Agonists Hypertrophic Cardiomyopathy Efdoralprin Alfa COPD Treatment Eczema Treatments Dupixent HIV Prevention Monoclonal Antibodies DREAMM Trials Sickle Cell Disease Treatments Cardiovascular Drugs Cosentyx Schizophrenia Treatments Amgen Safety Concerns Opioid Crisis PURPOSE Trials LDL Cholesterol Management